Statements (25)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
gptkb:drug |
| gptkbp:ATCCode |
none (as of 2024)
|
| gptkbp:CASNumber |
gptkb:1496510-51-0
|
| gptkbp:clinicalTrialPhase |
Phase 2 (solid tumors)
Phase 3 (Cushing's syndrome) |
| gptkbp:developedBy |
gptkb:Corcept_Therapeutics
|
| gptkbp:hasMolecularFormula |
C27H27F4N3O3
|
| gptkbp:hasSMILES |
C1=CC(=CC=C1C#N)NC(=O)C2=CC3=C(C=C2)C4(CC5=CC=CC=C5C6=CC=CC=C64)C3
|
| https://www.w3.org/2000/01/rdf-schema#label |
Relacorilant
|
| gptkbp:investigatedBy |
gptkb:cancer
gptkb:Cushing's_syndrome adrenocortical carcinoma solid tumors |
| gptkbp:IUPACName |
(4aR,6aS,6bS,8aR,10aS,12aR,14aS,14bR)-N-(4-cyanophenyl)-6a,8a,10a,12a,14a,14b-hexafluoro-2,4,4a,5,6,6a,6b,7,8,8a,9,10,10a,11,12,12a,13,14,14a,14b-icosahydro-1H-pyrazolo[3,4-g]isoquinoline-3-carboxamide
|
| gptkbp:legalStatus |
investigational
|
| gptkbp:mechanismOfAction |
glucocorticoid receptor antagonist
|
| gptkbp:molecularWeight |
517.52 g/mol
|
| gptkbp:PubChem_CID |
gptkb:CHEMBL4297592
71587768 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:synonym |
CORT125134
|
| gptkbp:UNII |
6Q1K1VJ0ZV
|
| gptkbp:bfsParent |
gptkb:Corcept_Therapeutics
|
| gptkbp:bfsLayer |
7
|